23andMe scores $82.5M, after a difficult year

Sequoia Capital and NewView Capital participated in the latest funding round.

After a year of financial struggles, consumer genomics company 23andMe raised just under $82.5 million in equity funding, according to SEC filings. Veteran health tech investors Sequoia Capital and NewView Capital participated in this latest round, according to the Wall Street Journal.

Historically, 23andMe has had a number of large investments, including a $300 million investment from pharma giant GSK in 2018; a $250 million round in 2017, which was led by Sequoia; and a $79 million round in 2015.